Corrigendum to "Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC" [Chem. Biol. Interact. (2021) 109652]
1 Department of Oncology, Taizhou Clinical Medical School of Nanjing Medical University, Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China; Department of Radiotherapy, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.
2 Department of Oncology, Taizhou Clinical Medical School of Nanjing Medical University, Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China.
3 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.
4 Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.
5 Department of Oncology, Taizhou Clinical Medical School of Nanjing Medical University, Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China. Electronic address: hanghuyan888@163.com.
6 Department of Radiotherapy, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China. Electronic address: liuyongbs996@163.com.